Maddi Hebebrand, MC, Associate Editor

Hypothyroidism and Hashimoto's thyroiditis were found to significantly increase the risk of developing AA, unlike hyperthyroidism.

A recent study indicated that 43.3% of lesions achieved a high efficacy score following Alexandrite laser therapy.

Researchers behind the review suggested that future research should prioritize large-scale trials to confirm abrocitinib's long-term safety and efficacy in various skin disorders.

This marks the first head-to-head trial of an IL-17A/F inhibitor against an IL-23 inhibitor in psoriatic arthritis treatment.

The company plans to release full 52-week OLE data for ESK-001 in early 2025, building on positive interim results.

After releasing promising data from several clinical trials, Burnett discussed the importance of studying efficacy and safety across diverse populations.

Nearly 44.2% of patients achieved HiSCR100, indicating a complete resolution of HS symptoms by the end of the 2-year period.

Key highlights of the presentations included data on delgocitinib for atopic hand eczema, and tralokinumab for head and neck atopic dermatitis.

“It is critical that our clinical data represent the diversity in the world around us, and these results further reinforce our commitment to providing meaningful innovation for immune-mediated skin diseases," said Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis.

The findings stem from post-hoc analyses of previous trials, which found that 75.1% of patients reached PASI100 after 1 year on bimekizumab.

Through collaboration with Nimbus Therapeutics and Schrodinger, zasocitinib’s AI-driven design maximizes its fit within the targeted enzyme.

Mona Shahriari, MD, FAAD, shared insights into prevalence, clinical presentations, increasing research diversity, and advocating for representation.

The study found that over 80% of patients who responded to lebrikizumab at week 16 maintained clear or almost-clear skin after 3 years.

Christopher Bunick, MD, PhD, shared insights into zasocitinib’s presented data and ongoing clinical trials.

Learn more about the latest in dermatology from Sheila Fallon Friedlander, MD; Melodie Young, MSN, ANP-c; Raj Chovatiya, MD, PhD, MSCI; Julie Harper, MD; and Matthew Zirwas, MD.

Announcements from both the FDA and the EC were supported by 2 clinical trials that evaluated the safety and efficacy of delgocitinib cream.

Zelma Chiesa Fuxench, MD, MSCE, FAAD, and Mona Shahriari, MD, FAAD, discuss the lack of research into psoriasis in skin of color, the absence of diversity in clinical trial populations, and where dermatology as a discipline can go from here.

Catch up on coverage from the fourth day of the Maui Derm NP+PA Fall 2024 conference in Nashville, Tennessee.

Hilary Baldwin, MD, emphasized involving patients in the decision-making process to create a personalized and cost-effective plan.

During an interview with Dermatology Times, Zirwas outlined modern allergens such as sulfites, dietary nickel, and acrylates.

Catch up on coverage from the third day of the Maui Derm NP+PA Fall 2024 conference in Nashville, Tennessee.

From dupilumab to OX40s, Zirwas talked about the niche to all atopic dermatitis therapies to make the best decision with your patient.

In a session at Maui Derm NP+PA Fall, Zirwas talked about the newfound discoveries of causation within the AD space.

Del Rosso’s cases emphasized the importance of thorough patient evaluation and communication with other health care providers.

Catch up on coverage from the second day of the Maui Derm NP+PA Fall 2024 conference in Nashville, Tennessee.

During his session at Maui Derm NP+PA Fall, Hawkes emphasized the need for careful patient communication and shared his excitement for remibrutinib.

Researchers analyzed APPs treatment and perceptions on AD in studies focusing on patient satisfaction and patients with skin of color.

Catch up on coverage from the first day of the Maui Derm NP+PA Fall 2024 conference in Nashville, Tennessee.

Hawkes highlights groundbreaking therapies for psoriasis, including new oral medications and IL-23 inhibitors.

The IL-13 inhibitor, recently FDA-approved for moderate to severe AD, reached all primary endpoints in the study focusing on patients with skin of color.